Literature DB >> 34135467

Expression patterns for Bcl-2, EMA, β-catenin, E-cadherin, PAX8, and MIB1 in thymomas.

David Suster1, James A Miller2, German Pihan1, A Craig Mackinnon3, Saul Suster4.   

Abstract

The expression of immunohistochemical markers has been extensively investigated in thymomas to assist in the differential diagnosis. We have studied six select markers to determine their utility in the evaluation of these tumors. A series of 126 thymomas including 33 type A, 27 type AB, 20 type B1, 22 type B2, and 24 type B3, were examined utilizing a tissue microarray (TMA) technique with antibodies to e-cadherin, β-catenin, PAX8, bcl-2, EMA, and MIB-1. Keratin AE1/AE3 and p63 were used for quality control. A significant finding was strong and consistent positivity for bcl-2 in type A (90%) and type AB (88.8%) thymoma, while 100% of B1, B2, and B3 were negative. The distribution of e-cadherin and β-catenin was not useful for differential diagnosis. E-cadherin and β-catenin were expressed in a high proportion of all the tumors (92-100%), except for B2 thymoma which showed only 45% expression. A significant increase in the expression of the MIB-1 proliferation marker (mean: 12.8% nuclear positivity) was also observed in B3 thymoma compared with the other histologic types. Statistical significance was confirmed using Kruskal's non-parameterized test for distribution. EMA was generally negative except for spindle cells in the fibrous septa in types A and AB thymoma. PAX8 showed less consistent nuclear staining than p63 and was only widely expressed in 55.7% of cases. Bcl-2 may serve as a useful marker to separate spindle cell thymomas (Type A and AB) from the other types, and the MIB1 proliferation index may be of use to differentiate type B2 from type B3 thymoma.
© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34135467     DOI: 10.1038/s41379-021-00839-1

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  47 in total

1.  Thymoma: a clinicopathologic study.

Authors:  P E BERNATZ; E G HARRISON; O T CLAGETT
Journal:  J Thorac Cardiovasc Surg       Date:  1961-10       Impact factor: 5.209

2.  Reproducibility of 3 histologic classifications and 3 staging systems for thymic epithelial neoplasms and its effect on prognosis.

Authors:  Anja C Roden; Eunhee S Yi; Sarah M Jenkins; Kelly K Edwards; Janis L Donovan; Jean E Lewis; Stephen D Cassivi; Randolph S Marks; Yolanda I Garces; Marie Christine Aubry
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

3.  Controversies in the pathology of thymoma viewed through the prism of evidence-based pathology.

Authors:  Alberto M Marchevsky; Mark R Wick
Journal:  Oncology (Williston Park)       Date:  2012-10       Impact factor: 2.990

4.  An immunohistochemical study of thymic epithelial tumors. I. Epithelial component.

Authors:  T Kodama; S Watanabe; Y Sato; Y Shimosato; N Miyazawa
Journal:  Am J Surg Pathol       Date:  1986-01       Impact factor: 6.394

5.  Classification of thymic epithelial neoplasms is still a challenge to thoracic pathologists: a reproducibility study using digital microscopy.

Authors:  Hangjun Wang; Camelia S Sima; Mary Beth Beasley; Peter Illei; Anjali Saqi; Daisuke Nonaka; Kim R Geisinger; James Huang; Andre L Moreira
Journal:  Arch Pathol Lab Med       Date:  2014-05       Impact factor: 5.534

6.  Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.

Authors:  Chin-Chen Pan; Paul Chih-Hsueh Chen; Teh-Ying Chou; Hung Chiang
Journal:  Hum Pathol       Date:  2003-11       Impact factor: 3.466

7.  An immunohistochemical study of thymic epithelial tumors. II. Lymphoid component.

Authors:  Y Sato; S Watanabe; K Mukai; T Kodama; M P Upton; M Goto; Y Shimosato
Journal:  Am J Surg Pathol       Date:  1986-12       Impact factor: 6.394

8.  D2-40 Antibody is a Specific Marker for B2 Thymomas.

Authors:  Malgorzata Szolkowska; Renata Langfort; Sebastian Winiarski; Piotr Rudzinski; Dorota Giedronowicz; Ewa Szczepulska-Wojcik; Piotr Ronduda; Beata Maksymiuk; Tadeusz Orlowski
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017-07

9.  Cytokeratins in normal thymus and thymic epithelial tumors.

Authors:  I Fukai; A Masaoka; T Hashimoto; Y Yamakawa; T Mizuno; O Tanamura
Journal:  Cancer       Date:  1993-01-01       Impact factor: 6.860

10.  Interobserver variation in the classification of thymic tumours--a multicentre study using the WHO classification system.

Authors:  E T Verghese; M A den Bakker; A Campbell; A Hussein; A G Nicholson; A Rice; B Corrin; D Rassl; G Langman; H Monaghan; J Gosney; J Seet; K Kerr; S K Suvarna; M Burke; P Bishop; S Pomplun; S Willemsen; B Addis
Journal:  Histopathology       Date:  2008-08       Impact factor: 5.087

View more
  1 in total

1.  Atypical thymomas with squamoid and spindle cell features: clinicopathologic, immunohistochemical and molecular genetic study of 120 cases with long-term follow-up.

Authors:  David I Suster; A Craig Mackinnon; Marcello DiStasio; Malay Kumar Basu; German Pihan; Saul Suster
Journal:  Mod Pathol       Date:  2022-02-10       Impact factor: 8.209

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.